AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01976923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab
Description: A sterile lid speculum is used to separate the lids. A subconjunctival injection of 1% lidocaine is applied to the inferotemporal quadrant. A 5% povidone iodine solution is used to disinfect the entire conjunctival surface. 1.25 mg / 0.05 mL of bevacizumab is injected using a 30-gauge needle inserted through the inferotemporal pars plana 3.5 mm from the limbus.
Study NCT01976923 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Small-gauge pars plana vitrectomy
Study NCT01976923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small-gauge pars plana vitrectomy
Study NCT02800200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Sono-guided injection with 3 cc Platelet rich plasma were performed in both groups.
Study NCT02800200 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Platelet rich plasma
Description: Sono-guided injection with 3 cc Platelet rich plasma were performed in both groups.
Study NCT02800200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock wave
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
Study NCT02800200 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: shock wave
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 whole virus vaccine, IM, 1.5microg
Description: influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 whole virus vaccine, IM, 5microg
Description: influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 whole virus vaccine vaccine, IM, 15microg
Description: influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 whole virus vaccine, IM, 45microg
Description: influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 whole virus vaccine, alum, IM, 1.5microg
Description: influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 whole virus, alum, IM, 5microg
Description: influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 vaccine, whole virus, alum, IM, 15 microg
Description: influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 vaccine, whole virus, alum, IM, 45microg
Description: influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 virosome vaccine, IM, 1.5microg
Description: influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 virosomal vaccine, IM, 5microg
Description: influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 virosomal vaccine, IM, 15microg
Description: influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 virosomal vaccine, IM, 45microg
Description: influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 whole virus vaccine, ID, 5microg
Description: influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
Study NCT00814229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H9N2 whole virus vaccine, ID, 15microg
Description: influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
Study NCT00305578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine will be given orally. Subjects will be started at a dose of 5 mg for the first week and then increased by 5 mg every week up to a maximum of 20 mg depending on response and tolerance and will be kept at that level for the rest of the study. This is an 8 week study.
Study NCT00305578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active medication, only placebo
Study NCT00288093 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Study NCT00288093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triapine
Study NCT04418687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthoglide
Description: Knee rehabilitation device.
Study NCT04418687 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy only
Description: Physiotherapy only.
Study NCT00847587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel contraceptive implant
Description: Implant insertion postpartum prior to hospital discharge
Study NCT00847587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etonogestrel contraceptive implant
Description: Standard insertion at 4-8 weeks postpartum
Study NCT01407926 — intervention group
Intervention type: OTHER
Intervention: Nurse-Led Mental Health Promotion Intervention
Description: The nurse-led intervention is a multi-faceted 6-month program led by a Registered Nurse that involves regular home visits, monthly case conferences, and evidence-based assessment and management of depression using an interprofessional approach.
Study NCT05055180 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive hemodynamics and myocardial biopsies
Description: Invasive hemodynamic characterization (biventricular pressure volume loop assessment) and biventricular myocardial biopsies
Study NCT02687399 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the placebo group will receive placebo for inyection sprayed on the exposed tissues of the knee.
Study NCT02687399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TT-173
Description: After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the treatment group will receive TT-173 for inyection sprayed on the exposed tissues of the knee.
Study NCT03924986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg administered intravenously (IV)
Study NCT03924986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match Tislelizumab
Study NCT03924986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabin
Description: 1 g/m2, administered as an IV infusion within 30 minutes
Study NCT03924986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabin
Description: 1 g/m2, administered as an IV infusion within 30 minutes
Study NCT03924986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m2, administered as an IV infusion over 4 hours
Study NCT03924986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2, administered as an IV infusion over 4 hours
Study NCT00963898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target controlled infusion(TCI), Bispectral index(BIS)
Description: Using TCI and BIS or not
Study NCT00358787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crossed K-wiring of supracondylar fracture of the humerus
Description: Closed reduction of the fracture followed by crossed K wire percutaneous pinning.
Study NCT00358787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral K-wiring of supracondylar fracture of the humerus
Description: Closed reduction of the fracture followed by lateral K wire percutaneous pinning.
Study NCT04407559 — intervention group
Intervention type: OTHER
Intervention: Serological analyses to be lead on a pre-existing biobank
Description: 3 immunoassays will be used according to the procedure described (Demey-2020; Tuaillon-2020) :~* WuHan UNscience Biotechnology Co., Ltd (Chine). COVID-19 IgG/IgM Rapid Test Kit, (Wuhan, China), will be refered as UNscience~* Chongqing iSIA BIO-Technology Co., Ltd (Chine). 2019-nCoV IgM/IgG Diagnostic Test Kit ; (Chongqing, China), will be refered as iSIA~* Xiamen Biotime Biotechnology Co. Ldt (Chine). (SARS-CoV-2) IgM/IgG Rapid Qualitative Test Kit, will be refered as Biotime.
Study NCT01564615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Umbilical catheterization (AgION )
Description: Infants received a AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
Study NCT01564615 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical catheterization (ArgyleTM)
Description: Infants received a polyurethane non-impregnated catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
Study NCT01394445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physostigmine
Description: continuous intravenous infusion per syringe pump (13 vials of 2 mg/5 ml --> 26 mg/65 ml; 1 ml = 0.4 mg Physostigmine) at rate of 1 mg/h (2.5ml/h) for 24 hours
Study NCT01394445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: continuous intravenous infusion of 65 ml NaCl 0.9% with syringe pump at rate of 2.5 ml/h for 24 hours~PCA: Patient-controlled analgesia with hydromorphone 0.2 mg/ml, on demand: bolus of 0.2 mg, maximum 5 boli per hour; 4-hour-maximum 4 mg
Study NCT03622099 — intervention group
Intervention type: DRUG
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
Study NCT04313829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist Counseling Intervention
Description: We used the counseling module (in the form of a guide book) for pharmacist-based counseling that had been validated regarding constructive content by an endocrinologist and a pharmacist expert in diabetes drug counseling. The module explained the T2DM causes and symptoms, the reasons for the importance of therapy, the non-pharmacological and pharmacological therapies available (drug names, strengths, indications, rules of use, side effects, interactions, and storage), the purpose of controlling blood sugar levels, medications that need to be avoided, and guidelines for missed doses. The pharmacists should explain all the content within the module in 15 minutes to each patient of the intervention group each month for 6 months. As an ethical consideration, the control group patients were given the same explanation module through pharmacist counseling after the study finished.
Study NCT05056025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbotics and Vitamins
Description: 2 capsule 3 times a day, before meals
Study NCT05056025 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamins
Description: 2 capsule 3 times a day, before meals
Study NCT01058343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFN-K
Description: 3 to 4 IM injections over 3 months
Study NCT01058343 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IFN-K
Description: 3 to 4 IM injections over 3 months
Study NCT02216838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A
Description: A total of 10U will be injected at 1cm increments by the blinded dermatologist into the respective randomized side.
Study NCT02216838 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Control
Description: A total of 0.5cc benzyl alcohol containing saline will be injected at 1cm increments by the blinded dermatologist into the respective randomized side
Study NCT00159289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inhalation of LPS
Study NCT00159289 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02406807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA manipulation
Description: participant is laying on the left side, the practitioner stands in front of the participant's abdomen. The practitioner contacts the interspinous space of the L5-S1 level with the caudal; with the cephalic hand, the practitioner rotates the participant's upper body until a sense of tension is palpated at the L5-S1 segment. The practitioner places his cephalic hand at interspinous, brings participant's leg to a flexion and places the foot at the popliteal fossa, places the forearm at the participant's deltopectoral groove and the caudal forearm at the gluteal region. Following the participant's expiration, the practitioner brings the L5-S1 level to the restrictive barrier by rotating the trunk and hips to opposite directions.
Study NCT02406807 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Spinal lumbar manipulation
Description: Sham manipulation
Study NCT01033409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella Typhi-vectored pneumonia vaccine
Description: Liquid, oral dosage administered once at 10\^7 CFU in 10 mL phosphate-buffered saline
Study NCT01033409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella Typhi-vectored pneumonia vaccine
Description: Liquid, oral dosage administered once at 10\^8 CFU in 10 mL phosphate-buffered saline
Study NCT01033409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella Typhi-vectored pneumonia vaccine
Description: Liquid, oral dosage administered once at 10\^9 CFU in 10 mL phosphate-buffered saline
Study NCT01033409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella Typhi-vectored pneumonia vaccine
Description: Liquid, oral dosage administered once at 10\^10 CFU in 10 mL phosphate-buffered saline
Study NCT01123252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus casei Shirota (LcS)
Description: Subjects will receive one bottle of Yakult containing the probiotic bacterium Lactobacillus casei Shirota (active drink) once daily for 4 months (16 weeks).
Study NCT01123252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive one bottle of a placebo milk drink, once daily for 4 months (16 weeks).
Study NCT03657901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music listening
Description: Guided music listening for 30 minutes before sleep onset
Study NCT03657901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow breathing
Description: Guided slow breathing for 30 minutes before sleep onset
Study NCT03273166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00001
Description: This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
Study NCT03273166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control SpHb sensor
Description: This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
Study NCT03273166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodilution
Description: This is a non-randomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers while undergoing a hemodilution procedure.
Study NCT03021993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered on days 1, 15 and 29. If disease has progressed at day 29, the subject will proceed to surgery. If a response or stable disease is present after the third dose, a fourth dose will be given on day 43, then the subject will proceed to surgery.
Study NCT01531855 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose
Description: Dosage after exercise
Study NCT02398006 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a standard arm sling
Description: Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
Study NCT02398006 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a figure-of-eight bandage
Description: Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
Study NCT02492607 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: wide local excision only or wide local excision and radiotherapy or mastectomy.~+/- hormonal therapy
Study NCT02492607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital mammography
Description: annual mammography
Study NCT02492607 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: according local policy
Study NCT01282463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel: 75 milligram/square meter (mg/m2) on Day 1 of each 21-day cycle
Study NCT01282463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: 75 milligram/square meter (mg/m2) on Day 1 of each 21-day cycle
Study NCT01282463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab DP
Description: Ramucirumab (DP): 10 milligram/kilogram (mg/kg) intravenous (IV) on day 1 of each 21-day cycle
Study NCT01282463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Icrucumab
Description: 12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle
Study NCT00732407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aliskiren
Description: Aliskiren will be given in a preliminary dosage of 150 mg per day, after a follow up of two weeks dosage will be increased to 300 mg per day.
Study NCT00732407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: Losartan will be given in a preliminary dosage of 50 mg per day and after a two weeks follow up dosage will be increased to 100 mg per day
Study NCT04188444 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood test
Description: 20 ml of blood, three times
Study NCT01870934 — intervention group
Intervention type: DEVICE
Intervention: Camera
Description: No real intervention, but a comparison of different methods including the new medical device 3D camera.
Study NCT04381546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation FES
Description: Functional electrical stimulation (FES) is delivered to the quadriceps and hamstrings of the paretic limb in patients with hemiplegia. It is based on the real-time estimation of the knee angle and support phase during gait.
Study NCT01571544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal suit
Description: Thermal suit
Study NCT01571544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional clothing
Description: Conventional clothing
Study NCT05780424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRII-196
Description: BRII-196 is a fully human immunoglobulin G (IgG)-1 monoclonal antibody (mAb) derived from antibody P2C-1F11 that was isolated directly from human B cells of a convalescent COVID-19 patient.
Study NCT05780424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRII-198
Description: BRII-198 is a fully human IgG-1 mAb derived from antibody P2B-1G5 that was isolated directly from human B cells of a convalescent COVID-19 patient.
Study NCT05780424 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% sodium chloride solution
Study NCT05780424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Antiviral agent